Navigation Links
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Date:6/27/2008

xis' quality of science and productivity," said Paolo Poletti, MD, senior vice president of the Oncology Medicines Development Center at GSK.

"The GSK collaboration was critical to the development of Exelixis' world- class discovery group and our rapidly expanding clinical development group. Today, we have a pipeline of 11 compounds in clinical development, including XL184, which begins a phase 3 trial this summer," said George A. Scangos, president and chief executive officer of Exelixis. "This collaboration has been successful in that both companies have been able to share in the output of our discovery and development efforts and will be able to take forward multiple promising compounds with significant commercial potential in oncology. With the successful completion of the collaboration, we will have clarity regarding the exclusivity obligations under the GSK collaboration and ownership of the compounds in our pipeline."

To date, Exelixis has received approximately $235 million from GSK, which includes $150 million in upfront, milestone, and R&D support payments, and $85 million through a loan facility. Additionally, if GSK selects a second compound for further development, Exelixis will be entitled to receive an additional milestone payment of either $55 million or $27.5 million. The milestone will be due after the selected compound achieves proof-of-concept and will be creditable by GSK against amounts outstanding under the loan facility. Exelixis is eligible for development milestones and royalties on compounds selected for development and commercialization by GSK, which include XL880 and potentially one additional compound if GSK exercises its second development election. Exelixis will pay GSK a low, single-digit royalty on certain "Refused Candidates" that GSK elected not to choose with its development election which Exelixis thereafter successfully commercializes.

Background on Exelixis-GSK Collaboration

In October 2002, Exelixi
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Research and Markets ... for Pulp & Paper Industry Report 2014" report ... for Pulp & Paper Industry Report 2014 is a ... the global enzyme for pulp & paper industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:8/27/2014)... August 27, 2014 Riviera Beach, ... announcing the creation of the Sancilio Scientific Advisory ... the SCI’s philosophy of looking to nature for ... development actions are based on sound scientific data, ... Advisory Board provides a vehicle for SCI to ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Remcom announces ... with new features for the biomedical industry. ... enhanced Biological Thermal Sensor, exclusive to the Bio-Pro version ... version of XFdtd, developed to calculate the biological effects ... has been added to all versions to expand engineers’ ...
(Date:8/26/2014)... 26, 2014  NeuroSigma, Inc., a Los ... bioelectronic technologies, today announced that it has filed a ... and Exchange Commission relating to a proposed initial public ... to be offered and the price range for the ... Jefferies LLC will act as the book-running manager for ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... As the exclusive official,breaking news service for North ... is featuring profiles of the exhibiting,organizations. The profile Perry ... Perry Baromedical Corporation Booth Number: ... : http://www.perrybaromedical.com Perry Baromedical Corporation is ...
... Implementation Issues and Recommendations, BETHLEHEM, Pa., ... of Clinical Value Marketing, Infusion Systems Division ... Services for B. Braun Medical,Inc. (B. Braun), ... and services,recently represented B. Braun at the ...
... 12 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today ... 2008. For the three-month period, the Company posted,revenue of ... Cash and cash,equivalents totaled $14.3 million at September 30, ... productive as we further,our transition to a development-only company," ...
Cached Biology Technology:Perry Baromedical Corporation Exhibiting at MEDICA 2008 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 3TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 2TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 3TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 4TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 5TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 6TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 7
(Date:8/27/2014)... LAKE CITY, Aug. 27, 2014 University of Utah ... his native Turkey, has won that nation,s highest science ... of Science. , Sekercioglu is among five researchers picked ... and Technical Research Council of Turkey. Three researchers won ... won the Special Award, which is equivalent to the ...
(Date:8/27/2014)... what is described by the Volunteer Wildfire Services of ... Cape provincial government warned residents in certain parts of ... veld fires. A high veld fire danger rating ... coast in the Great Kei and Mnquma area. ... thunderstorms. The thunderstorms bring lightning strikes and subsequent ...
(Date:8/27/2014)... release is available in German . ... is the most common inherited disease affecting the peripheral ... the Max Planck Institute of Experimental Medicine and University ... Schwann cells is impaired in rats with the disease. ... layer known as myelin, which facilitates the rapid transfer ...
Breaking Biology News(10 mins):University of Utah biologist wins Turkey's top science prize 2Potential therapy for incurable Charcot-Marie-Tooth disease 2
... biochemists are now able to access 3D images ... than relying on text to provide the understanding ... now provides a new resource by linking written ... resource, first described in BioMed Central,s open access ...
... at The University of Manchester have developed a new ... that could lead to quick testing for serious diseases, ... new drugs. Researchers working at the Manchester Interdisciplinary ... a new technique for producing functional ,protein chips, in ...
... St. Andrews, United Kingdom, have helped determine why relearning a ... a recollection of other associated, previously learned information. The ... learned information is forgotten. Details are published August 22nd ... When one learns a language and then doesn,t use it, ...
Cached Biology News:Chips are down as Manchester makes protein scanning breakthrough 2
... modifications of Eagle's medium have ... formulation. The most widely used ... DME is a modification of ... that contains a higher concentration ...
... Hollandes is a fixative useful for ... fixation. It is stable and will decalcify ... with Hollande's can be stained successfully with ... the solution stabilizes red blood cell membranes ...
... Shimadzus GCMS-QP2010s Gas Chromatograph/Mass Spectrometer, utilizing ... the GCMS-QP2010 Plus, offers high throughput ... an excellent performance-to-cost ratio. Like the ... constant linear velocity for optimum separation, ...
... The Precision XS uniquely combines a ... head and an 8-channel bulk reagent dispenser ... addition to transfers using disposable pipette tips, ... resistant bulk reagent dispenser is available for ...
Biology Products: